pomalidomide has been researched along with caffeine in 1 studies
| Studies (pomalidomide) | Trials (pomalidomide) | Recent Studies (post-2010) (pomalidomide) | Studies (caffeine) | Trials (caffeine) | Recent Studies (post-2010) (caffeine) |
|---|---|---|---|---|---|
| 623 | 121 | 552 | 25,501 | 2,393 | 6,825 |
| Protein | Taxonomy | pomalidomide (IC50) | caffeine (IC50) |
|---|---|---|---|
| Acetylcholinesterase | Homo sapiens (human) | 7.25 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hoffmann, M; Li, Y; Liu, L; Palmisano, M; Reyes, J; Wang, X; Zhang, C; Zhou, S | 1 |
1 trial(s) available for pomalidomide and caffeine
| Article | Year |
|---|---|
In Vivo Assessment of the Effect of CYP1A2 Inhibition and Induction on Pomalidomide Pharmacokinetics in Healthy Subjects.
Topics: Adult; Aged; Area Under Curve; Caffeine; Cigarette Smoking; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inducers; Cytochrome P-450 CYP1A2 Inhibitors; Drug Interactions; Fluvoxamine; Half-Life; Healthy Volunteers; Humans; Male; Middle Aged; Thalidomide | 2018 |